StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)

Wed, 15 Jul 2026 07:40:55 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ: CRVO).

The analyst commented: "In a press release yesterday, CervoMed reported the presentation of new analyses highlighting insights into neflamapimod's treatment effects in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference (AAIC) 2026 in London, UK. The analyses included treatment effects during the placebo-controlled portion of CervoMed’s previously-conducted Phase 2b trial, as well as the impact of achieving higher plasma drug concentrations relative to placebo during the trial's extension phase. They also included pharmacokinetic and pharmacodynamic (PK/PD) relationships for neflamapimod and its

Form 8-K CervoMed Inc. For: Jul 14

Tue, 14 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260714/26768527.html

Form 8-K CervoMed Inc. For: Jul 14

Tue, 14 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260714/26768527.html

CervoMed presents neflamapimod DLB trial data at AAIC 2026

Tue, 14 Jul 2026 07:32:28 -0400

CervoMed Inc. (NASDAQ: CRVO) presented new analyses of its neflamapimod drug candidate in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference in London on July 14, 2026.

The data came from new analyses of the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension. The company said the trial's primary endpoint was not met, attributing this to a higher-than-targeted proportion of patients with Alzheimer's disease co-pathology and a drug product batch that did not achieve expected plasma concentrations.

Exploratory analyses showed that patients with low plasma pTau181 levels — below 21

CervoMed presents neflamapimod DLB trial data at AAIC 2026

Tue, 14 Jul 2026 07:32:28 -0400

Exploratory analyses showed that patients with low plasma pTau181 levels — below 21

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

Tue, 14 Jul 2026 07:30:00 -0400

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in “pure” DLB and support selection of 50 mg TID for planned Phase 3 study in DLB

Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

Tue, 14 Jul 2026 07:30:00 -0400

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in “pure” DLB and support selection of 50 mg TID for planned Phase 3 study in DLB

Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic

H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)

Mon, 13 Jul 2026 06:40:08 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ: CRVO).
The analyst commented: "Late last week, CervoMed reported that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of non-fluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia (FTD). Interim biomarker data from the study will be presented at the 19th CTAD Conference in Boston, Massachusetts, taking place November 16–19, 2026. Initial clinical therapeutic activity top-line data at 24 weeks shall be presented in 1Q27. The Phase 2a study was designed to evaluate the safety, pharmacokinetics, and

Form EFFECT CervoMed Inc.

Mon, 13 Jul 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260713/26759171.html

Form EFFECT CervoMed Inc.

Mon, 13 Jul 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260713/26759171.html

Form 424B3 CervoMed Inc.

Fri, 10 Jul 2026 17:27:00 -0400
si-local-file:///var/storage/secattach/20260710/26758086.html

Form 424B3 CervoMed Inc.

Fri, 10 Jul 2026 17:27:00 -0400
si-local-file:///var/storage/secattach/20260710/26758086.html

Form 8-K CervoMed Inc. For: Jul 09

Thu, 09 Jul 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260709/26753303.html

Form 8-K CervoMed Inc. For: Jul 09

Thu, 09 Jul 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260709/26753303.html

CervoMed completes enrollment in Phase 2 nfvPPA dementia trial

Thu, 09 Jul 2026 07:30:14 -0400

CervoMed Inc. (NASDAQ: CRVO) has completed enrollment in its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia (FTD) with no approved treatments in the U.S. or European Union.

The trial enrolled 25 participants who are taking oral neflamapimod — either 40 milligrams three times daily (19 participants) or 80 milligrams twice daily (6 participants) — for 24 weeks, followed by a 12-week randomized, double-blind, placebo-controlled extension. The study is evaluating safety, pharmacokinetics, and clinical effects of the drug at academic medical centers in the U.S.

Interim biomarker data from the trial will

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Thu, 09 Jul 2026 07:30:00 -0400

Interim biomarker data accepted for presentation at the 19^th Clinical Trials on Alzheimer's Disease (CTAD) conference

Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a therapeutic target and support neflamapimod's potential to treat frontotemporal dementia (FTD) driven by tau pathology

Nonfluent variant primary progressive aphasia (nfvPPA), the type of FTD most commonly associated with tau pathology, has no approved treatments in the United States or European Union

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Thu, 09 Jul 2026 07:30:00 -0400

Interim biomarker data accepted for presentation at the 19^th Clinical Trials on Alzheimer's Disease (CTAD) conference

Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a therapeutic target and support neflamapimod's potential to treat frontotemporal dementia (FTD) driven by tau pathology

Nonfluent variant primary progressive aphasia (nfvPPA), the type of FTD most commonly associated with tau pathology, has no approved treatments in the United States or European Union

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for

H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)

Thu, 09 Jul 2026 06:53:18 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ: CRVO).
The analyst commented: "We remind investors that CervoMed has reached alignment with global regulatory authorities in finalizing the design for the company’s planned Phase 3 trial in patients who have dementia with Lewy bodies (DLB). CervoMed selected 50mg three times per day of a stable crystal form of neflamapimod as the dose and dosing regimen that will be used for the company’s planned Phase 3 trial in patients with DLB. A single, global, randomized, double-blind, placebo-controlled Phase 3 trial of neflamapimod is slated to

Form SCHEDULE 13G/A CervoMed Inc. Filed by: MORGAN STANLEY

Wed, 08 Jul 2026 17:43:00 -0400
si-local-file:///var/storage/secattach/20260708/26748487.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: MORGAN STANLEY

Wed, 08 Jul 2026 17:43:00 -0400
si-local-file:///var/storage/secattach/20260708/26748487.html

CervoMed (CRVO) for 10.08M share offering by selling stockholders

Mon, 06 Jul 2026 17:05:22 -0400

CervoMed (NASDAQ: CRVO) has filed for up to 10,081,131 share offering by selling stockholders.

CervoMed (CRVO) for 10.08M share offering by selling stockholders

Mon, 06 Jul 2026 17:05:22 -0400

CervoMed (NASDAQ: CRVO) has filed for up to 10,081,131 share offering by selling stockholders.

Form S-3 CervoMed Inc.

Mon, 06 Jul 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260706/26736422.html

Form S-3 CervoMed Inc.

Mon, 06 Jul 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260706/26736422.html

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

Mon, 06 Jul 2026 07:30:00 -0400

Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies

CervoMed’s science to be featured in five presentations at AAIC

BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that the upcoming AAIC meeting will feature five presentations highlighting the company’s clinical science, including four on neflamapimod, its oral, small molecule, drug candidate